INTRODUCTION: No standard guideline has been established for the treatment of plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and show resistance to commonly used cytostatic drugs. PATIENT CONCERNS: We present the case of a 52-year-old HIV-negative man who presented with a mass at the left sternoclavicular joint. He had no significant comorbidities and no latent immunosuppression. DIAGNOSIS: The largest lymph node measured was 36 × 19 mm. An excisional biopsy showed diffuse proliferation of large lymphoid cells which were positive for CD38 and CD138, but negative for CD20. He was diagnosed with stage IV PBL with a low IPI. INTERVENTIONS: The patient was treated with four cycles of induction therapy with bortezomib, epirubicin and dexamethasone. He achieved complete remission. But 3 months after receiving consolidated autologous hematopoietic stem cell transplantation, he relapsed. Allogeneic hematopoietic stem cell transplantation was performed on the patient. OUTCOMES: The patient achieved remission again and there were no serious complications after allogeneic hematopoietic stem cell transplantation. This patient was followed up once every three months, and to date, he has been disease-free for more than 4 years. CONCLUSION: The survival of recurrent PBL after autologous hematopoietic stem cell transplantation is very poor. Salvage allogeneic hematopoietic stem cell transplantation may bring long-term survival opportunities for those patients. Further clinical studies are needed to explore the role of allogeneic hematopoietic stem cell transplantation in refractory and recurrent PBL.
INTRODUCTION: No standard guideline has been established for the treatment of plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and show resistance to commonly used cytostatic drugs. PATIENT CONCERNS: We present the case of a 52-year-old HIV-negative man who presented with a mass at the left sternoclavicular joint. He had no significant comorbidities and no latent immunosuppression. DIAGNOSIS: The largest lymph node measured was 36 × 19 mm. An excisional biopsy showed diffuse proliferation of large lymphoid cells which were positive for CD38 and CD138, but negative for CD20. He was diagnosed with stage IV PBL with a low IPI. INTERVENTIONS: The patient was treated with four cycles of induction therapy with bortezomib, epirubicin and dexamethasone. He achieved complete remission. But 3 months after receiving consolidated autologous hematopoietic stem cell transplantation, he relapsed. Allogeneic hematopoietic stem cell transplantation was performed on the patient. OUTCOMES: The patient achieved remission again and there were no serious complications after allogeneic hematopoietic stem cell transplantation. This patient was followed up once every three months, and to date, he has been disease-free for more than 4 years. CONCLUSION: The survival of recurrent PBL after autologous hematopoietic stem cell transplantation is very poor. Salvage allogeneic hematopoietic stem cell transplantation may bring long-term survival opportunities for those patients. Further clinical studies are needed to explore the role of allogeneic hematopoietic stem cell transplantation in refractory and recurrent PBL.
Authors: Jane Jijun Liu; Ling Zhang; Ernesto Ayala; Teresa Field; Jose L Ochoa-Bayona; Lia Perez; Celeste M Bello; Paul A Chervenick; Salvador Bruno; Jennifer L Cultrera; Rachid C Baz; Mohamed A Kharfan-Dabaja; Jyotishankar Raychaudhuri; Eduardo M Sotomayor; Lubomir Sokol Journal: Leuk Res Date: 2011-07-12 Impact factor: 3.156
Authors: Andrew D Zelenetz; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; John C Byrd; Myron S Czuczman; Luis Fayad; Andres Forero; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Mark S Kaminski; Youn H Kim; Ann S Lacasce; Tariq I Mughal; Auyporn Nademanee; Pierluigi Porcu; Oliver Press; Leonard Prosnitz; Nashitha Reddy; Mitchell R Smith; Lubomir Sokol; Lode Swinnen; Julie M Vose; William G Wierda; Joachim Yahalom; Furhan Yunus Journal: J Natl Compr Canc Netw Date: 2010-03 Impact factor: 11.908
Authors: Jorge J Castillo; Michael Furman; Brady E Beltrán; Michele Bibas; Mark Bower; Weina Chen; José L Díez-Martín; Jane J Liu; Roberto N Miranda; Silvia Montoto; Nahid M Nanaji; José-Tomás Navarro; Adam C Seegmiller; Julie M Vose Journal: Cancer Date: 2012-04-17 Impact factor: 6.860
Authors: Ariela Noy; Shelly Y Lensing; Page C Moore; Neel Gupta; David Aboulafia; Richard Ambinder; Robert Baiocchi; Bruce J Dezube; David Henry; Lawrence Kaplan; Alexandra M Levine; Ronald Mitsuyasu; Lee Ratner; Erin Reid; Scot Remick; Joseph Sparano; Dimitrios Tzachanis; William Wachsman; Amy Chadburn Journal: Leuk Lymphoma Date: 2015-12-16